Zhong Ji Longevity Science Group Limited
中基長壽科學集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

SUPPLEMENTAL ANNOUNCEMENT DIVERSITY OF BOARD MEMBERS UNDER RULE 13.92 OF THE LISTING RULES

Reference is made to the announcement of Zhong Ji Longevity Science Group Limited (the "**Company**") dated 17 October 2025 in relation to the resignation of Mr. Yan Yifan ("**Mr. Yan**") as an as an executive Director and chief executive officer and Ms. Cao Xie Qiong (the "**Ms. Cao**") as an executive Director of the Company ("**Director(s)**") with effect from 17 October 2025 (the "**Effective Date**") due to their devotion to their personal and other business commitments; and Mr. Yan Li ("**Mr. Yan Li**"), an executive Director, has been appointed as the Chief Executive Officer of the Company with effect from 17 October 2025 (the "**Announcement**"). Pursuant to Rule 13.92 of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"), the Stock Exchange will not consider diversity to be achieved for a single gender board. Code Provision B.3.5 of the Corporate Governance Code as set out in Appendix C1 ("**Code Provision B.3.5**") of the Listing Rules states that the Company should appoint at least one director of a different gender to the nomination committee. The Company has no other female Directors following the resignation of Ms. Cao Xie Qiong from the Effective Date as announced by the Company in the Announcement and has a single gender board which does not meet the requirement under Rule 13.92 of the Listing Rules and the Code Provision B.3.5.

Following the resignation of Ms. Cao, the Company has taken active steps to identify suitable candidates that meet relevant requirements (including but not limited to, gender, age, cultural background, educational qualifications, professional expertise, and industry and regional experience). The nomination committee will evaluate these criteria when identifying and selecting candidates for Board directorships, ensuring that they align with the corporate strategy and enhance Board diversity as appropriate. Despite all our efforts, additional time is needed for the Company to identify potential candidates for female Directors. The Company will further expand the scope of the selection process and continue to actively seek and approach potential suitable candidates. It is expected that the Board will appoint a suitable female candidate as Director as soon as practicable and not later than 17 January 2026 in order to ensure compliance by the Company with the requirement under Rule 13.92 of the Listing Rules and the Code Provision B.3.5. The Company will make further announcements in due course.

APPOINTMENT OF CHIEF EXECUTIVE OFFICER

Reference to the Announcement, Mr. Yan Li, an executive director of the Company, was appointed as the Chief Executive Officer ("**CEO**") of the Company with effect from 17 October 2025. The Company would like to clarify that, Mr. Yan Li has entered into an appointment letter with the Company regarding his appointment as the CEO, pursuant to which Mr. Yan Li shall receive an annual remuneration of HK$1.2 million including salaries, bonuses and other benefits, being executive director and the chairman of the Company. Consider Longevity science business undergone transformation stage now, Mr. Yan Li agreed to take over additional CEO role without further annual remuneration, bonuses and other benefits. But any revisions to this CEO role remuneration arrangement shall be determined by the Remuneration Committee and finalised by the Board of directors with further update announcement promptly made therein, if any.

The Company confirms that the above supplemental information provided in this announcement does not affect other information contained in the Announcement and save as disclosed above, all other information in the English and Chinese versions of the Announcement is correct and remains unchanged. This announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Zhong Ji Longevity Science Group Limited
Yan Li
Chairman, Chief Executive Officer and Executive Director

Hong Kong, 7 November 2025

As at the date of this announcement, the Directors are:

Executive Directors
Mr. Yan Li
(Chairman and Chief Executive Officer)
Mr. Li Xiaoshuang

Non-executive Directors
Dr. He Yiwu
Mr. Lyu Changshang

Independent Non-executive Directors
Mr. Lee See Barry
Mr. Huang Jiang
Prof. Huang Cibo

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.